Barclays Initiates Coverage On RAPT Therapeutics with Overweight Rating, Announces Price Target of $35
Portfolio Pulse from richadhand@benzinga.com
Barclays analyst Leon Wang initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with an Overweight rating and a price target of $35.
June 15, 2023 | 9:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays initiates coverage on RAPT Therapeutics with an Overweight rating and a price target of $35.
Barclays initiating coverage on RAPT Therapeutics with an Overweight rating and a price target of $35 indicates a positive outlook for the stock. This news is likely to have a positive impact on RAPT's stock price in the short term as investors may see this as a sign of confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100